Impact of belantamab mafodotin vs pomalidomide/low-dose dexamethasone treatment on health-related quality of life and vision-related functioning in patients with relapsed/refractory multiple myeloma

被引：0

作者：

Dimopoulos, Meletios ^{[1
]}

Weisel, Katja ^{[2
]}

Hungria, Vania ^{[3
]}

Sapra, Sandhya ^{[4
]}

Sule, Neal ^{[4
]}

Li, Mary ^{[4
]}

McKeown, Astrid ^{[5
]}

Kazeem, Gbenga ^{[5
]}

Polinkovsky, Margaret ^{[6
]}

Meunier, Juliette ^{[7
]}

Loubert, Angely ^{[7
]}

Bunod, Laurine ^{[7
]}

Perera, Sue ^{[8
]}

Currie, Brooke ^{[9
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Athens, Greece

[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[3] Clin Sao Germano, Dept Hematol, Sao Paulo, Brazil

[4] GSK, Upper Providence, PA USA

[5] GSK, Stevenage, Herts, England

[6] GSK, Durham, NC USA

[7] Modus Outcomes, Lyon, France

[8] GSK, London, England

[9] GSK, Rockville, MD USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-252

引用

页码：S174 / S175

页数：2

共 50 条

[31] Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial
Weisel, Katja
Dimopoulos, Meletios A.
San-Miguel, Jesus
Paner, Agne
Engelhardt, Monika
Taylor, Fiona
Lord-Bessen, Jennifer
Yip, Christine
Greenwood, Mike
Tang, Jackson
Cavo, Michele
HEMASPHERE, 2023, 7 (03): : E843
[32] Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
Chen, Christine I.
Sutherland, Heather J.
Kotb, Rami
Sebag, Michael
White, Darrell J.
Bensinger, William
Gasparetto, Cristina J.
Leblanc, Richard
Venner, Christopher P.
Lentzsch, Suzanne
Schiller, Gary J.
Lipe, Brea
Del Col, Aldo
Shah, Jatin J.
Jeha, Jacqueline
Saint-Martin, Jean-Richard
Kauffman, Michael G.
Shacham, Sharon
Bahlis, Nizar
BLOOD, 2018, 132
[33] Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone +/- subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial
Terpos, Evangelos
Dimopoulos, Meletios A.
Boccadoro, Mario
Delimpasi, Sosana
Beksac, Meral
Katodritou, Eirini
Moreau, Philippe
Pompa, Alessandra
Symeonidis, Argiris
Bila, Jelena
Oriol, Albert
Mateos, Maria-Victoria
Einsele, Hermann
Orfanidis, Ioannis
Gries, Katharine S.
Fastenau, John
Liu, Kevin
He, Jianming
Kampfenkel, Tobias
Qiu, Yanping
Amin, Himal
Carson, Robin
Sonneveld, Pieter
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (04) : 481 - 490
[34] POMALIDOMIDE WITH LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE ANALYSIS IN A POPULATION-BASED REGISTRY
Wester, R.
Dinmohamed, A.
Sonneveld, P.
Broijl, A.
Blijlevens, N.
HAEMATOLOGICA, 2017, 102 : 533 - 534
[35] Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies
Richardson, Paul G.
Perrot, Aurore
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey S. Y.
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Mace, Sandrine
Malinge, Laure
Dubin, Franck
Morisse, Mony
Anderson, Kenneth C.
BLOOD, 2022, 140
[36] Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study
Del Giudice, Maria Livia
Gozzetti, Alessandro
Antonioli, Elisabetta
Orciuolo, Enrico
Ghio, Francesco
Ciofini, Sara
Candi, Veronica
Fontanelli, Giulia
Attucci, Irene
Formica, Giuseppe
Bocchia, Monica
Galimberti, Sara
Petrini, Mario
Buda, Gabriele
MEDICINA-LITHUANIA, 2021, 57 (09):
[37] Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance
Ludwig, Heinz
Ponisch, Wolfram
Egle, Alexander
Knop, Stefan
Schreder, Martin
Lechner, Daniel
Hajek, Roman
Gunsilius, Eberhard
Fridrik, Michael A.
Petzer, Andreas
Weisel, Katja C.
Niederwieser, Dietger
Hinke, Axel
Greil, Richard
Zojer, Niklas
BLOOD, 2017, 130
[38] Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis
Richardson, Paul
Perrot, Aurore
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey Shang-Yi
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Malinge, Laure
Dubin, Franck
Morisse, Mony
Anderson, Kenneth
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S32 - S32
[39] Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Impact of Renal Function on Patient Outcomes
Siegel, David S.
Richardson, Paul G.
Baz, Rachid
Chen, Min
Zaki, Mohamed
Anderson, Kenneth C.
BLOOD, 2012, 120 (21)
[40] Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Dimopoulos, Meletios A.
Weisel, Katja C.
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Moreau, Philippe
Banos, Anne
Oriol, Albert
Garderet, Laurent
Cavo, Michele
Ivanova, Valentina
Alegre, Adrian
Martinez-Lopez, Joaquin
Chen, Christine
Spencer, Andrew
Knop, Stefan
Bahlis, Nizar J.
Renner, Christoph
Yu, Xin
Hong, Kevin
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
San Miguel, Jesus F.
HAEMATOLOGICA, 2015, 100 (10) : 1327 - 1333

← 1 2 3 4 5 →